Enliven Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
ELVN$51.55+4.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
Exhibit Index
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date |
| 1.1 | Open Market Sale AgreementSM, dated June 23, 2023, by and between Enliven Therapeutics, Inc. and Jefferies LLC | 8-K | 001-39247 | 1.1 | June 26, 2023 |
| 2.1 | Agreement and Plan of Merger, dated as of October 13, 2022, by and among Imara Inc., Iguana Merger Sub, Inc. and Enliven Therapeutics, Inc. | 8-K | 001-39247 | 2.1 | October 13, 2022 |
| 3.1 | The Company's Restated Certificate of Incorporation, as amended June 18, 2024 | 10-Q | 001-39247 | 3.1 | August 13, 2024 |
| 3.2 | Amended and Restated Bylaws of the Registrant | 8-K | 001-39247 | 3.2 | March 16, 2020 |
| 4.1 | Specimen Common Stock Certificate of the Registrant | S-3 | 333-272909 | 4.1 | June 23, 2023 |
| 4.2 | Description of the Registrant’s Securities | 10-K | 001-39247 | 4.2 | March 14, 2024 |
| 4.3 | Form of Pre-Funded Warrant | 8-K | 001-39247 | 4.1 | March 19, 2024 |
| 4.4 | Form of Pre-Funded Warrant | 8-K | 001-39247 | 4.1 | June 16, 2025 |
| 10.1* | Contingent Value Rights Agreement between the Company and Rights Agent | 8-K | 001-39247 | 10.1 | March 1, 2023 |
| 10.2+ | Amended and Restated 2020 Equity Incentive Plan | 8-K | 001-39247 | 10.1 | June 18, 2024 |
| 10.3+ | 2020 Employee Stock Purchase Plan | 10-K | 001-39247 | 10.3 | March 14, 2024 |
| 10.4+ | Rahul Ballal Separation Agreement, dated February 23, 2023 | 8-K | 001-39247 | 10.6 | March 1, 2023 |
| 10.5+* | Sam Kintz Confirmatory Employment Letter, as amended and restated February 29, 2024 | 10-K | 001-39247 | 10.6 | March 14, 2024 |
| 10.6+* | Helen Collins Confirmatory Employment Letter, as amended and restated February 29, 2024 | 10-K | 001-39247 | 10.7 | March 14, 2024 |
| 10.7+* | Benjamin Hohl Confirmatory Employment Letter, as amended and restated February 29, 2024 | 10-K | 001-39247 | 10.8 | March 14, 2024 |
| 10.8+* | Joseph Lyssikatos Confirmatory Employment Letter, as amended and restated February 29, 2024 | 10-K | 001-39247 | 10.9 | March 14, 2024 |
| 10.9+* | Anish Patel Confirmatory Employment Letter, as amended and restated February 29, 2024 | 10-K | 001-39247 | 10.10 | March 14, 2024 |
| 10.10+#* | Richard Fair Offer Letter, effective December 11, 2025 | 8-K | 001-39247 | 10.1 | December 11, 2025 |
| 10.11+ | Sam Kintz Change in Control and Severance Agreement, as amended and restated February 29, 2024 | 10-K | 001-39247 | 10.11 | March 14, 2024 |
| 10.12+ | Helen Collins Change in Control and Severance Agreement, as amended and restated February 29, 2024 | 10-K | 001-39247 | 10.12 | March 14, 2024 |
| 10.13+ | Benjamin Hohl Change in Control and Severance Agreement, as amended and restated February 29, 2024 | 10-K | 001-39247 | 10.13 | March 14, 2024 |
| 10.14+ | Joseph Lyssikatos Change in Control and Severance Agreement, as amended and restated February 29, 2024 | 10-K | 001-39247 | 10.14 | March 14, 2024 |
| 10.15+ | Anish Patel Change in Control and Severance Agreement, as amended and restated February 29, 2024 | 10-K | 001-39247 | 10.15 | March 14, 2024 |
| 10.16+#*† | Sam Kintz Transition Agreement and Release, effective December 10, 2025 | Filed herewith | |||
| 10.17+ | Richard Fair Change in Control and Severance Agreement, effective December 11, 2025 | 8-K | 001-39247 | 10.2 | December 11, 2025 |
| 10.18+ | Outside Director Compensation Policy, as amended January 1, 2026 | Filed herewith | |||
| 10.19+ | Form of Indemnification Agreement of the Company | 8-K | 001-39247 | 10.16 | March 1, 2023 |
| 10.20+ | Enliven 2019 Equity Incentive Plan, as amended, including forms of agreements thereunder | S-4 | 333-268300 | 10.2 | November 10, 2022 |
| 10.21+ | Employee Incentive Compensation Plan | 8-K | 001-39247 | 10.18 | March 1, 2023 |
| 10.22+ | Enliven Therapeutics, Inc. 2025 Inducement Equity Incentive Plan and related form of stock option agreement | 8-K | 001-39247 | 10.3 | December 11, 2025 |
| 10.23 | Securities Purchase Agreement, dated March 19, 2024, by and among the Company and the Purchasers named therein | 8-K | 001-39247 | 10.1 | March 19, 2024 |
| 10.24+ | Form of Stock Option Agreement under the Registrant’s Amended and Restated 2020 Equity Incentive Plan | Filed herewith | |||
| 10.25+ | Form of Restricted Stock Unit Agreement under the Registrant’s Amended and Restated 2020 Equity Incentive Plan | Filed herewith | |||
| 19.1 | Insider Trading Policy | Filed herewith | |||
| 21.1 | List of Subsidiaries of Enliven Therapeutics, Inc. | Filed herewith | |||
| 23.1 | Consent of Independent Registered Public Accounting Firm | Filed herewith | |||
| 24.1 | Power of Attorney (included on the signature page to this Annual Report on Form 10-K) | Filed herewith | |||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed herewith | |||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed herewith | |||
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Furnished herewith | |||
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Furnished herewith | |||
| 97.1 | Compensation Recovery Policy | 10-K | 001-39247 | 97.1 | March 14, 2024 |
| 101.INS | INLINE XBRL Instance Document | Furnished herewith | |||
| 101.SCH | INLINE XBRL Taxonomy Extension Schema with Embedded Linkbase Documents | Furnished herewith | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Furnished herewith | |||
| + | Management contract or compensatory plan. |
|---|---|
| # | Certain exhibits or schedules to this exhibit have been omitted in compliance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. |
| * | Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6). |
| † | Certain confidential information contained in this document, marked by [†††], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. |
| ** | The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Enliven Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.